Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choe, Won Hyeok | - |
dc.contributor.author | Hong, Sun Pyo | - |
dc.contributor.author | Kim, Byung Kook | - |
dc.contributor.author | Ko, Soon Young | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Kim, Kyun-Hwan | - |
dc.contributor.author | Ji, Seung Il | - |
dc.contributor.author | Kim, Soo-Ok | - |
dc.contributor.author | Lee, Chang Hong | - |
dc.contributor.author | Kwon, So Young | - |
dc.date.accessioned | 2021-09-08T21:25:00Z | - |
dc.date.available | 2021-09-08T21:25:00Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1359-6535 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/120923 | - |
dc.description.abstract | Background: The efficacy of entecavir (ETV) monotherapy in treatment-experienced patients with chronic hepatitis B (CHB) is debatable. Methods: A total of 22 hepatitis B e antigen (HBeAg)positive CHB patients who had shown viral breakthrough or suboptimal response with lamivudine (3TC) and adefovir disoproxil (ADV) therapy were treated with 1.0 mg of ETV. Clinical and virological parameters were monitored every 3 months. Restriction fragment mass polymorphism assays were used to detect antiviral resistance. Results: During 3TC and ADV therapy, 11 patients had rtM204V/I mutations, 2 had rtA181V/T or rtN236T. 7 had both and 2 had no 3TC- or ADV-related mutations. After switching to ETV monotherapy, the median change in serum hepatitis B virus (HBV) DNA level was -2.1 log(10) copies/ml. Virological response (HBV DNA<300 copies/ml) was achieved in 1 of 18 patients with pre-existing rt204 mutations, whereas it was achieved in all 4 patients without pre-existing rt204 mutations regardless of the presence of rt181 or rt236 mutations. Changes in mutational patterns during ETV therapy showed that rt204 mutations persisted or re-emerged. Relative abundances of rtM204V/I mutations in total viral populations gradually increased under ETV rescue, whereas those with rtA181V/T and rtN236T mutations decreased. ETV resistance mutations (rtL180M+rtT1841/L[rtS2026]+rtM204V) were detected in five patients with pre-existing rt204 mutations. Conclusions: ETV monotherapy resulted in a limited virological response in patients who had previously failed 3TC and ADV rescue therapy. The limited efficacy might be associated with residual or reselected rtM204V/I mutations leading to ETV resistance. Combination treatment including potent antiviral agents should be recommended for patients with pre-existing rtM204V/I mutations. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | INT MEDICAL PRESS LTD | - |
dc.subject | NUCLEOSIDE-NAIVE PATIENTS | - |
dc.subject | HEPATOCELLULAR-CARCINOMA | - |
dc.subject | DNA LEVEL | - |
dc.subject | MANAGEMENT | - |
dc.subject | DIPIVOXIL | - |
dc.subject | MUTANTS | - |
dc.subject | RISK | - |
dc.subject | INFECTION | - |
dc.subject | CIRRHOSIS | - |
dc.subject | EFFICACY | - |
dc.title | Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.identifier.doi | 10.3851/IMP1417 | - |
dc.identifier.scopusid | 2-s2.0-72249122581 | - |
dc.identifier.wosid | 000272060000011 | - |
dc.identifier.bibliographicCitation | ANTIVIRAL THERAPY, v.14, no.7, pp.985 - 993 | - |
dc.relation.isPartOf | ANTIVIRAL THERAPY | - |
dc.citation.title | ANTIVIRAL THERAPY | - |
dc.citation.volume | 14 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 985 | - |
dc.citation.endPage | 993 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | NUCLEOSIDE-NAIVE PATIENTS | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | DNA LEVEL | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DIPIVOXIL | - |
dc.subject.keywordPlus | MUTANTS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | EFFICACY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.